title: [Targeted therapy in thyroid cancer: Towards a treatment card].
abstract: Thyroid cancer is an uncommon cancer. Molecular biology plays a vital role in its development. Chemotherapy showed unsatisfactory results in advanced stages where surgery and iodine therapy are not appropriate. These last ten years have been marked by a major advance in understanding the molecular features of this cancer and therapeutic correlations, moreover, clinical trials have focused on the treatment of this disease on metastatic stages and led to a significant therapeutic panel targeting angiogenesis, mutations frequently found in cervical cancer: RET, BRAF, RAS... these are the motesanib, axitinib, sunitinib, pazopanib, vandetanib, cabozotinib and sorafenib. The last three molecules have already the autorisation of FDA and EMA. In this review, we will put the item on oncogenetic characteristics of thyroid carcinoma as well as new targeted therapies in patients refractory to conventional treatment.
authors.affiliation: Service d'oncologie médicale, institut national d'oncologie Moulay-Abdellah, rue Lamfadel-Cherkaoui Rabat Institut, BP 6527, 10000 Rabat, Maroc. Electronic address: s.lkhoyaali@gmail.com.
authors.forename: S
authors.initials: S
authors.lastname: Lkhoyaali
authors.affiliation: Service d'oncologie médicale, institut national d'oncologie Moulay-Abdellah, rue Lamfadel-Cherkaoui Rabat Institut, BP 6527, 10000 Rabat, Maroc.
authors.forename: S
authors.initials: S
authors.lastname: Benhmida
authors.affiliation: Service d'oncologie médicale, institut national d'oncologie Moulay-Abdellah, rue Lamfadel-Cherkaoui Rabat Institut, BP 6527, 10000 Rabat, Maroc.
authors.forename: M
authors.initials: M
authors.lastname: Ait Elhaj
authors.affiliation: Service d'oncologie médicale, institut national d'oncologie Moulay-Abdellah, rue Lamfadel-Cherkaoui Rabat Institut, BP 6527, 10000 Rabat, Maroc.
authors.forename: M
authors.initials: M
authors.lastname: Layachi
authors.affiliation: Service d'oncologie médicale, institut national d'oncologie Moulay-Abdellah, rue Lamfadel-Cherkaoui Rabat Institut, BP 6527, 10000 Rabat, Maroc.
authors.forename: Y
authors.initials: Y
authors.lastname: Bensouda
authors.affiliation: Service d'oncologie médicale, institut national d'oncologie Moulay-Abdellah, rue Lamfadel-Cherkaoui Rabat Institut, BP 6527, 10000 Rabat, Maroc.
authors.forename: H
authors.initials: H
authors.lastname: Errihani
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods / Q000639:trends; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D057285:Precision Medicine / Q000379:methods / Q000639:trends*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D051096:Proto-Oncogene Proteins c-ret / Q000037:antagonists & inhibitors / Q000235:genetics; D013964:Thyroid Neoplasms / Q000453:epidemiology / Q000235:genetics / Q000628:therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D051096:Proto-Oncogene Proteins c-ret; C099282:RET protein, human
keywords: Biologie moléculaire; Cancer de la thyroïde; Molecular biology; Targeted therapy; Thyroid cancer; Thérapies ciblées